Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BA3361
- Development stage
- Unknown
- Lead developer
- BioAtla
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
BA3361 is a conditionally and reversibly active antibody drug conjugate (ADC) developed by BioAtla for the treatment of multiple solid tumors. It targets Nectin-4, a cell-cell adhesion molecule that is overexpressed in various human malignancies. The drug uses BioAtla’s Conditionally Active Biologic (CAB) technology to enhance tumor selectivity and reduce off-target toxicity. Its next-generation carbohydrate linker system improves serum stability and hydrophilicity, aiming to increase potency while minimizing side effects. Preclinical data have shown complete tumor regression in several xenograft models and superior efficacy compared to an enfortumab vedotin analogue in pancreatic cancer models[1][5][7].
- Other names
- CAB-Nectin4-ADCCAB-Nectin-4-ADCCAB-Nectin 4-ADC
02
Targets
PVRL4 (Nectin cell adhesion molecule 4)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on BA3361.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BA3361.